Category: Latest News
-
Jabil pledges $1.1 million to St. Petersburg College for manufacturing workforce programs
Jabil Inc. (NYSE:JBL) announced it will donate $1.1 million over three years to St. Petersburg College to support training programs focused on advanced manufacturing, according to a company press release. The funding is intended to broaden student access to manufacturing technology, laboratory equipment and the raw materials commonly used in production environments. It will also…
-
AMC reports second-strongest box office weekend of 2026
AMC Theatres (NYSE:AMC) said the film Project Hail Mary delivered the company’s biggest opening weekend of 2026, helping drive its second-highest weekend of the year for admissions revenue both in the United States and globally. The movie, distributed by Amazon MGM, generated more than $140 million in worldwide box office revenue during its opening weekend.…
-
Logistics stocks rise after pause in Iran military strikes
Shares of logistics companies moved higher on Tuesday after President Donald Trump announced a five-day delay to further military strikes targeting Iranian power plants and energy infrastructure. GXO Logistics (NYSE:GXO) gained 2.25%, leading the sector’s advance. FedEx (NYSE:FDX) rose 1.71%, UPS (NYSE:UPS) added 0.93%, and Kirby (NYSE:KEX) edged up 0.30%. Trump said the pause followed…
-
Mobileye shares climb after securing major driver monitoring system contract
Mobileye (NASDAQ:MBLY) shares gained 6% on Monday after the company announced it had secured a significant production program for its Driver Monitoring System (DMS) with a major U.S. automaker. Under the agreement, Mobileye’s DMS technology will be incorporated into upcoming vehicles using the company’s EyeQ6L system-on-chip, with production expected to begin in 2027. The new…
-
Apogee Therapeutics shares surge on encouraging eczema drug trial results
Shares of Apogee Therapeutics (NASDAQ:APGE) jumped 15% on Monday after the company reported positive 52-week results from Part A of its Phase 2 APEX study evaluating zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis. The data showed that treatment responses were maintained through 52 weeks with both quarterly and twice-yearly dosing schedules. Among patients who…
-
Insmed shares rise on positive results from ARIKAYCE Phase 3b study
Shares of Insmed Incorporated (NASDAQ:INSM) climbed 6.6% on Monday after the company reported positive topline data from its Phase 3b ENCORE clinical trial evaluating ARIKAYCE. The study achieved its primary endpoint as well as all multiplicity-controlled secondary culture conversion endpoints, showing statistically significant improvements in both respiratory symptom scores and culture conversion rates. Patients receiving…
-
Rubrik adds integration with Microsoft Defender to strengthen identity attack recovery
Rubrik (NYSE:RBRK) said it has integrated its platform with Microsoft Defender (NASDAQ:MSFT), linking real-time identity threat detection with automated tools for identity rollback and system recovery. The collaboration was unveiled at the RSAC 2026 conference. The integration enables organizations to feed Microsoft Defender alerts directly into Rubrik’s identity recovery workflows. This allows security teams to…
-
CrowdStrike unveils new AI security capabilities for endpoint protection
CrowdStrike (NASDAQ:CRWD) introduced new features for its Falcon platform aimed at strengthening AI agent discovery and runtime protection across endpoints, software-as-a-service platforms, web browsers and cloud environments. The cybersecurity firm said its sensors currently detect more than 1,800 different AI applications operating on enterprise devices, accounting for nearly 160 million unique application instances across its…
-
Arnold Magnetic Technologies signs rare earth magnet distribution deal with USA Rare Earth
Arnold Magnetic Technologies Corporation, a unit of Compass Diversified (NYSE:CODI), has entered into a mutual sales and distribution agreement with USA Rare Earth Inc. (NASDAQ:USAR) covering rare earth permanent magnets. Under the non-exclusive arrangement, both companies will be able to market and distribute each other’s products while continuing to operate as independent contractors. Arnold will…
-
Tarsus to receive $15M milestone after China approves TP-03 eye therapy
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) said it will receive a $15 million milestone payment after China’s National Medical Products Administration approved TP-03 (lotilaner ophthalmic solution) 0.25%. The approval was secured by Grand Pharmaceutical Group Limited, Tarsus’ partner responsible for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region,…